NASDAQ$SIBN
SI-BONE Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for Q1 2024.
SI-BONE, Inc. reported a worldwide revenue of $37.9 million, a 16% increase compared to the prior year period. The company updated its 2024 worldwide revenue guidance to be in the range of $164 million to $166 million.
- Worldwide revenue increased by ~16% to $37.9 million.
- U.S. revenue increased by ~16% to $35.4 million.
- Gross margin was ~79%.
- Over 1,100 U.S. active physicians, representing an increase of ~16%.
Headline financials
Revenue & EPS history
SI-BONE · Revenue · Quarterly
$37.9M
Forward guidance
SI-BONE updated 2024 worldwide revenue guidance to be in the range of $164 million to $166 million, an increase from the previous guidance of $162 million to $165 million.
Tailwinds
- Annual guidance increased to $164 million - $166 million.
- Implies annual growth of ~18% - 20%.
- Expansion of opportunity in the pelvic fixation market with the rollout of the smaller diameter Granite implant.
- Building on the success of iFuse 3D with the adoption of TORQ across all our call points.
- Top-line growth will allow the company to make significant progress towards adjusted EBITDA breakeven goal.
Headwinds
- SI-BONE's ability to introduce and commercialize new products and indications.
- SI-BONE's ability to maintain favorable reimbursement for procedures using its products.
- The impact of any future economic weakness on the ability and desire of patients to undergo elective procedures including those using SI-BONE's devices.
- SI-BONE's ability to manage risks to its supply chain.
- Future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-1.8%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-0.8%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+16.2%
Q4 2022
Best reaction
-23.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | +15.3% | — | |
| Q4 2025 | -1.0% | -0.6% | -17.8% | |
| Q3 2025 | +16.1% | +11.1% | +20.0% | |
| Q1 2025 | +15.6% | +29.8% | +33.8% | |
| Q4 2024 | +5.6% | +3.7% | -19.9% | |
| Q3 2024 | -17.5% | -18.8% | -14.5% | |
| Q2 2024 | -3.6% | -5.2% | +10.2% | |
| Q1 2024 | +10.4% | +8.0% | -1.1% | |
| Q4 2023 | -12.4% | -15.7% | -22.0% | |
| Q3 2023 | -4.7% | -12.4% | -0.9% | |
| Q2 2023 | -12.5% | -9.6% | -7.1% | |
| Q1 2023 | +9.6% | -0.3% | +13.9% | |
| Q4 2022 | +16.2% | +19.5% | +14.0% | |
| Q3 2022 | -23.1% | -16.4% | -26.5% | |
| Q2 2022 | -6.4% | +0.1% | +3.5% | |
| Q1 2022 | -23.7% | -27.6% | -12.2% | |
| Q4 2021 | +2.4% | +3.2% | +3.2% | |
| Q3 2021 | -7.8% | -10.9% | -13.6% | |
| Q2 2021 | -15.1% | -18.9% | -18.3% | |
| Q1 2021 | -7.0% | -7.5% | -17.2% | |
| Q4 2020 | +4.0% | +6.6% | +8.3% | |
| Q3 2020 | +3.2% | +0.5% | +10.7% | |
| Q2 2020 | +13.6% | +17.7% | +31.7% | |
| Q1 2020 | +9.0% | +11.9% | +16.3% | |
| Q4 2019 | -11.9% | -21.7% | -28.9% | |
| Q3 2019 | -4.4% | -4.5% | -0.6% | |
| Q2 2019 | +6.8% | +10.7% | +11.3% | |
| Q1 2019 | -3.9% | -8.1% | -1.5% | |
| Q4 2018 | -4.6% | -3.6% | -9.4% | |
| Q3 2018 | -3.0% | +4.8% | +10.5% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro